Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Liposomal melatonin targets mutant hematopoiesis and bone marrow remodeling in MPN

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSiddharth GuptaAMAlessandro MottaSESara Elsafy

Discussion

Loading...

Member takes

Overview

Observational analysis shows liposomal melatonin reduces oxidative stress in hematopoietic stem cells, suggesting a novel therapeutic strategy in myeloproliferative neoplasms.

Key Points

  • Liposomal melatonin significantly decreases oxidative stress in CD34+ hematopoietic stem cells, enhancing their viability and apoptosis.
  • Therapeutic efficacy of melatonin was confirmed by a reduction in neoplastic blood parameters and improved bone remodeling observed in murine models.
  • Investigative tools included gene set enrichment analysis and immunofluorescence, supporting the therapeutic potential of melatonin in hematological malignancies.
  • These findings imply that melatonin may provide a new direction in treating myeloproliferative neoplasms, with translational applications necessary for clinical validation.

Cite This Study

Gupta et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcdchttps://doi.org/10.1182/blood-2025-1493
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell transcriptomic studies reveal altered heterogeneity in CD41 enriched megakaryocytes after targeted therapy in myeloproliferative neoplasm2025
  2. 2EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)2025 · 2 citations
  3. 3Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms2025
  4. 4Disrupting a new NFkB-IL-6-JAK2-STAT cascade with novel NFkB inhibitors reduces primary myelofibrosis growth2025
  5. 5Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor2025